Literature DB >> 15205761

[Tick-borne human pathogenic microorganisms found in Europe and those considered nonpathogenic. Part II: Bacteria, parasites and mixed infections].

J Süss1, V Fingerle, K-P Hunfeld, C Schrader, B Wilske.   

Abstract

The importance of tick-borne diseases has significantly increased objectively and subjectively during the last few years. This fact was demonstrated by the description of tick-borne viruses, in particular with respect to tickborne encephalitis published in part I. Here in part II, tick-borne bacteria and parasites will be discussed as well the significance of these agents, their vectors, clinical course, diagnostics, prophylaxis, and therapy. Naturally, Lyme borreliosis, one of the most important tick-borne bacterial illnesses of humans, is the center of our interest. In addition to basic understanding, critical practice-relevant advice regarding all agents is presented. Similarly all tick-borne bacterial diseases such as relapsing fever, tularemia, ehrlichiosis, and rickettsiosis including Q fever will be discussed. Tick-borne zoonotic babesiae are parasites whose veterinary importance has been known for the last 100 years but whose relevance for human medicine only became evident in 1957. The fact that multiple and mixed infections caused by ticks are possible has been known for years. Taking into account such a high prevalence of the infectious agents in ticks, such multiple infections were to be expected. During the last few years it has become evident that double and multiple infections of humans caused by tick bites occur far more frequently than has been known so far. As a result, in cases of unclear anamnesis,new diagnostic and therapeutic approaches should be taken. In general one can say that considerable additional scientific research is necessary to effectively reduce the incidence of tick-borne diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205761     DOI: 10.1007/s00103-004-0837-0

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  6 in total

1.  Three years of bluetongue disease in central Europe with special reference to Germany: what lessons can be learned?

Authors:  Helge Kampen; Doreen Werner
Journal:  Wien Klin Wochenschr       Date:  2010-10       Impact factor: 1.704

2.  Coxiella burnetii - Pathogenic Agent of Q (Query) Fever.

Authors:  Lutz Gürtler; Ursula Bauerfeind; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen
Journal:  Transfus Med Hemother       Date:  2013-12-23       Impact factor: 3.747

3.  Comparative population dynamics of a generalist (Ixodes ricinus) and specialist tick (I. hexagonus) species from European hedgehogs.

Authors:  M Pfäffle; T Petney; J Skuballa; H Taraschewski
Journal:  Exp Appl Acarol       Date:  2011-02-25       Impact factor: 2.132

4.  Seropositivity to Midichloria mitochondrii (order Rickettsiales) as a marker to determine the exposure of humans to tick bite.

Authors:  Valentina Serra; Viktoria Krey; Christina Daschkin; Alessandra Cafiso; Davide Sassera; Horst-Günter Maxeiner; Letizia Modeo; Carsten Nicolaus; Claudio Bandi; Chiara Bazzocchi
Journal:  Pathog Glob Health       Date:  2019-08-09       Impact factor: 2.894

5.  Tick infestation risk and Borrelia burgdorferi s.l. infection-induced increase in host-finding efficacy of female Ixodes ricinus under natural conditions.

Authors:  Michael K Faulde; Richard G Robbins
Journal:  Exp Appl Acarol       Date:  2008-02-14       Impact factor: 2.132

6.  Dynamics of distribution and efficacy of different spot-on permethrin formulations in dogs artificially infested with Dermacentor reticulatus.

Authors:  Johanna Lüssenhop; Wolfgang Bäumer; Manfred Kietzmann; Thomas Schnieder; Sonja Wolken
Journal:  Parasit Vectors       Date:  2011-03-30       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.